Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a heart drug rescue failing kidneys in the ICU?

NCT ID NCT01720030

Disease control Sponsor: VieCuri Medical Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether levosimendan, a drug used to support the heart, can also improve kidney function in adults with acute kidney injury in intensive care. Participants receive either levosimendan or a placebo, and their kidney function is measured daily. The goal is to see if this drug can help kidneys recover faster and reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levosimendan (Simdax), a drug given intravenously to support heart function and potentially protect the kidneys.
What this could lead to
If effective, levosimendan could offer a new way to help ICU patients recover kidney function during acute kidney injury, potentially reducing the need for dialysis.
What could go wrong
This is a mid-stage trial with a small number of participants, so results may not be conclusive. Levosimendan can affect blood pressure and heart rhythm, which requires careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

68 people

The number who actually took part.

Started

Sep 2016

Finished

Oct 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically diagnosed adult patients with AKI Exclusion Criteria: * Failure to obtain written consent to participate from patient or legal representative (by deferred consent) * Patients entering the ICU for post-operative observation with an estimated length of stay less than 24 hrs. * Moribund patients * Patients under the age of 18 * Pregnancy * Patients suffering from pre-existing renal failure (elevated NGAL values without apparent rise in creatinine values) * Renal replacement therapy initiated before admission due to Chronic Kidney Disease * Hypersensitivity to levosimendan experienced by previous treatments * Severe hypotension and tachycardia * Significant mechanical obstruction affecting ventricular filling or outflow or both. * Severe hepatic impairment (ALAT/ASAT\>400U/L) * Patients will be excluded if the treating physician judges that study participation is undesirable for medical, medical-ethical or other reasons * Known history of Torsades de Pointes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury

Contacts and locations

Locations

  • VieCuri Medical Center

    Venlo, Limburg, NL-5912 BL, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.